What is Onychomycosis Treatment Market?
Onychomycosis is the infection in nails due to the fungi like non-dermatophyte moulds, yeasts and dermatophytes. The onychomycosis is categorised as distal and lateral subungual onychomycosis, superficial white onychomycosis, proximal subungual onychomycosis, candidal onychomycosis. Onychomycosis treatment is required as it causes pain and further infection of the toenail and its treatment requires a longer time. It can be treated by systemic antifungal agents, lasers and photodynamic therapy. Systemic antifungal agents are increasingly used as it is most effective and has cure rates of 76% for terbinafine, 63% for itraconazole with pulse dosing, 59% for itraconazole with continuous dosage.
The market study is being classified, by Application (Hospitals, Dermatology Clinics, Retail Pharmacies and Online Pharmacies) and major geographies with country level break-up.
GlaxoSmithKline (United Kingdom), Pfizer Inc. (United States), Galderma S.A. (Switzerland), Reddy's Laboratories (UK) Ltd. (United Kingdom), Valeant Pharmaceuticals (Canada), Sanofi S.A. (France), Moberg Pharma (Sweden) and DermBiont, Inc (United States) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Onychomycosis Treatment market by Type, Application and Region.
On the basis of geography, the market of Onychomycosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Prevalence of Nails Funga Infection in People
- Need for the Treatment to Reduce the Pain and Further Infection Due to Fungi
- Increased Consumption of Systemic Antifungals Agents Because if its Effective Treatment Result
- Side Effects Related Risks with the Onychomycosis Treatment
- Surging Awwareess about the Infection-related Dangerous Diseases will Boost the Onychomycosis Treatment Market
- Emerging Number of Advanced Treatment for Onychomycosis
- regulatory guideline son the Production of and Supplying of Onychomycosis Medication
Market Leaders and some development strategies
On 21st October 2020, DermBiont, Inc., a clinical-stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. This strategic acquisition delivers multi-factorial value, and it expands the company's therapeutic pipeline with a first-in-class, targeted topical small molecule as well as our mission to address skin diseases at their root cause.
On 29th April 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for JUBLIA (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range included in the product's label to children six years of age and older.1 JUBLIA was first approved in June 2014 in patients 18 years and older.
Key Target AudienceOnychomycosis Treatment Providers, Onychomycosis Treatment Industry Association, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase